Your browser doesn't support javascript.
loading
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
Sidell, Douglas R; Balakrishnan, Karthik; Best, Simon R; Zur, Karen; Buckingham, Julia; De Alarcon, Alessandro; Baroody, Fuad M; Bock, Jonathan M; Boss, Emily F; Bower, Charles M; Campisi, Paolo; Chen, Sharon F; Clarke, Jeffrey M; Clarke, Kevin D; Cocciaglia, Alejandro; Cotton, Robin T; Cuestas, Giselle; Davis, Kara L; DeFago, Victor H; Dikkers, Frederik G; Dossans, Ines; Florez, Walter; Fox, Elizabeth; Friedman, Aaron D; Grant, Nazaneen; Hamdi, Osama; Hogikyan, Norman D; Johnson, Kaalan; Johnson, Liane B; Johnson, Romaine F; Kelly, Peggy; Klein, Adam M; Lawlor, Claire M; Leboulanger, Nicolas; Levy, Alejandro G; Lam, Derek; Licameli, Greg R; Long, Steve; Lott, David G; Manrique, Dayse; McMurray, James Scott; Meister, Kara D; Messner, Anna H; Mohr, Michael; Mudd, Pamela; Mortelliti, Anthony J; Novakovic, Daniel; Ongkasuwan, Julian; Peer, Shazia; Piersiala, Krysztof.
Afiliação
  • Sidell DR; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.
  • Balakrishnan K; Aerodigestive and Airway Reconstruction Center, Lucile Packard Children's Hospital Stanford, Stanford, California, U.S.A.
  • Best SR; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.
  • Zur K; Aerodigestive and Airway Reconstruction Center, Lucile Packard Children's Hospital Stanford, Stanford, California, U.S.A.
  • Buckingham J; Department of Otolaryngology-Head and Neck Surgery, Division of Laryngology, and, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
  • De Alarcon A; Division of Pediatric Otolaryngology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
  • Baroody FM; Maternal and Child Health Research Institute, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford University, Stanford, California, U.S.A.
  • Bock JM; Department of Otolaryngology, Division of Pediatric Otolaryngology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, U.S.A.
  • Boss EF; Section of Otolaryngology-Head and Neck Surgery and Department of Pediatrics, University of Chicago Medicine and The Comer Children's Hospital, Chicago, Illinois, U.S.A.
  • Bower CM; Department of Otolaryngology and Communication Sciences, Division of Laryngology and Professional Voice, Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A.
  • Campisi P; Department of Otolaryngology-Head and Neck Surgery and the Department of Health Policy and Management, Division of Pediatric Otolaryngology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
  • Chen SF; Department of Otolaryngology Head and Neck Surgery, Division of Pediatric Otolaryngology, University of Arkansas for Medical Sciences (UAMS), Arkansas Children's Hospital, Little Rock, Alaska, U.S.A.
  • Clarke JM; Department of Otolaryngology - Head and Neck Surgery, Hospital for Sick Children, University of Toronto, Toronto, Canada.
  • Clarke KD; Department of Pediatrics, Division of Infectious Diseases, Lucile Packard Children's Hospital Stanford, Stanford, California, U.S.A.
  • Cocciaglia A; Department of Medicine, Division of Oncology, Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, U.S.A.
  • Cotton RT; Pediatric Otolaryngology, Division of Otolaryngology Head and Neck Surgery, University of British Columbia (UBC, UVIc), Victoria General Hospital, Victoria, British Columbia, Canada.
  • Cuestas G; ENT-Respiratory Endoscopy Department, Garrahan Children's Hospital, Buenos Aires, Argentina.
  • Davis KL; Department of Otolaryngology, Division of Pediatric Otolaryngology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, U.S.A.
  • DeFago VH; Respiratory Endoscopy Section, ENT Department, Hospital General de Niños "Dr. Pedro de Elizalde", Buenos Aires, Argentina.
  • Dikkers FG; Department of Pediatrics, Division of Pediatric Oncology, Bass Center for Childhood Cancer and Blood Disorders, Stanford University, Stanford, California, U.S.A.
  • Dossans I; Pediatric Surgery, Sanatorio del Salvador Privado SA, Cordoba, Argentina.
  • Florez W; Department of Otorhinolaryngology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Fox E; Otolaryngology-Head and Neck Surgery, Hospital Pereira Rossell, Montevideo, Uruguay.
  • Friedman AD; Department of Otolaryngology, Instituto Nacional de Salud del Niño de San Borja, Lima, Peru.
  • Grant N; Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, Tennessee, U.S.A.
  • Hamdi O; Department of Otolaryngology, Head and Neck Surgery, University of Cincinnati School of Medicine, Cincinnati, Ohio, U.S.A.
  • Hogikyan ND; Department of Otolaryngology, Division of Laryngology, Medstar Georgetown University Hospital, Georgetown, Washington, District of Columbia, U.S.A.
  • Johnson K; Howard University College of Medicine, Washington, District of Columbia, U.S.A.
  • Johnson LB; Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.
  • Johnson RF; University of Washington School of Medicine, Department of Otolaryngology Head and Neck Surgery, Division of Pediatric Otolaryngology, Seattle, Washington, District of Columbia, U.S.A.
  • Kelly P; Department of Surgery, Dalhousie University, Division of Paediatric Otolaryngology-Head and Neck Surgery, IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Klein AM; Department of Otolaryngology-Head and Neck Surgery, University of Texas (UT) Southwestern Medical Center, Dallas, Texas, U.S.A.
  • Lawlor CM; Department of Otolaryngology, Head and Neck Surgery, Division of Pediatric Otolaryngology, Children's Hospital Colorado affiliated with University of Colorado, Anschutz, Aurora, Colorado, U.S.A.
  • Leboulanger N; Department of Otolaryngology-Head and Neck Surgery, Division of Laryngology, Emory Voice Center, Emory University School of Medicine, Atlanta, Georgia, U.S.A.
  • Levy AG; Department of Otolaryngology, Division of Pediatric Otolaryngology, Children's National Health System, George Washington University School of Medicine, Washington, District of Columbia, U.S.A.
  • Lam D; Head and Neck Surgery, Pediatric Otolaryngology, Necker Enfants Malades Hospital, Paris University, Paris, France.
  • Licameli GR; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Arnold Palmer Hospital Center for Children's Cancer and Blood Disorders, Orlando Health, Orlando, Florida, U.S.A.
  • Long S; Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon, U.S.A.
  • Lott DG; Department of Otolaryngology, Boston Children's Hospital, Boston, Massachusetts, U.S.A.
  • Manrique D; Department of Head and Neck Surgery, Kaiser Permanente, Hillsboro, Oregon, U.S.A.
  • McMurray JS; Department of Otorhinolaryngology, Division of Laryngology, Mayo Clinic Arizona, Phoenix, Arizona, U.S.A.
  • Meister KD; Department of Otorhinolaryngology, Universidad Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil.
  • Messner AH; Pediatric Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, U.S.A.
  • Mohr M; Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.
  • Mudd P; Aerodigestive and Airway Reconstruction Center, Lucile Packard Children's Hospital Stanford, Stanford, California, U.S.A.
  • Mortelliti AJ; Department of Otolaryngology/Head and Neck Surgery, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, U.S.A.
  • Novakovic D; Department of Hematology, Oncology and Respiratory Medicine, University Hospital Muenster, Muenster, Germany.
  • Ongkasuwan J; Department of Otolaryngology, Division of Pediatric Otolaryngology, Children's National Health System, George Washington University School of Medicine, Washington, District of Columbia, U.S.A.
  • Peer S; Department of Otolaryngology-Head and Neck Surgery, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, U.S.A.
  • Piersiala K; Department of Otolaryngology, Head and Neck Surgery, Central Clinical School, Faculty of Medicine and Health, University of Sydney, The Canterbury Hospital, Sydney, New South Wales, Australia.
Laryngoscope ; 131(6): E1941-E1949, 2021 06.
Article em En | MEDLINE | ID: mdl-33405268
ABSTRACT
OBJECTIVES/

HYPOTHESIS:

The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY

DESIGN:

Delphi method-based survey series.

METHODS:

A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.

RESULTS:

The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).

CONCLUSION:

This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. LEVEL OF EVIDENCE 5 Laryngoscope, 131E1941-E1949, 2021.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Inibidores da Angiogênese / Infecções por Papillomavirus / Bevacizumab Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Inibidores da Angiogênese / Infecções por Papillomavirus / Bevacizumab Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article